Cancer touches our lives in many ways.
Read about Orion's cancer researchStock exchange releases
- 10/29/2024 Orion Group Interim Report January–September 2024
- 10/24/2024 Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
- 9/20/2024 213,285 Orion Corporation A shares converted into B shares
- 9/11/2024 Inside information: Orion upgrades full-year outlook for 2024
Press releases
- 10/15/2024 Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
- 10/14/2024 Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
- 9/30/2024 Orion’s near-term climate targets approved by the Science Based Targets initiative
- 9/26/2024 Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
Latest articles
All articles
Päivi Kuoppamäki was diagnosed with COPD at the age of 40: “I av...
11/4/2024
Your Health
18-year-old Pyry shadowed the SVP for R&D for a day – “I would l...
10/30/2024
Orion and Society
Committed to science and sustainability: What do Orion’s science...
10/7/2024
Sustainability
Kerly Hiltunen was diagnosed with metastatic breast cancer: “I a...
10/1/2024
Your Health
Jenni Laukkanen: At Orion, my views are valued and that has made...
9/26/2024
We are Orion
